Chugai Gets Third US Breakthrough Status, For Hemophilia Antibody
This article was originally published in PharmAsia News
The US FDA has designated Chugai’s ACE910 as a breakthrough therapy for hemophilia A, making the bispecific antibody the first hemophilia treatment to receive the expedited review status, and marking the third project from the Japanese firm to receive the classification.
You may also be interested in...
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.